Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly Alimta could get advisory committee

Executive Summary

FDA is understood to be considering a July 27 Oncologic Drugs Advisory Committee review of Lilly's supplemental NDA for Alimta (pemetrexed) for use in second-line, non-small cell lung cancer. Lilly filed the sNDA in late October or early November, putting a 10-month user fee deadline in late August or early September. Alimta was approved Feb. 4 for malignant pleural mesothelioma (1"The Pink Sheet" Feb. 9, 2004, p. 20)...
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

PS043814

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel